PMID- 30475757
OWN - NLM
STAT- MEDLINE
DCOM- 20190611
LR  - 20200225
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Print)
IS  - 1574-0153 (Linking)
VI  - 24
IP  - 1
DP  - 2019
TI  - alpha2delta1 may be a potential marker for cancer stem cell in laryngeal squamous cell 
      carcinoma.
PG  - 97-107
LID - 10.3233/CBM-181947 [doi]
AB  - Cancer stem cells (CSCs) have the ability to dictate tumor initiation, 
      recurrence, and metastasis. Here, we examined the expression of aalpha2delta1+ in 
      laryngeal cancer tissues and further determined the effect of alpha2delta1 on the 
      migratory ability and tumorigenicity of laryngeal cancer cells. 
      Immunofluorescence staining revealed that alpha2delta1 was positive in 13 (13/16, 81.25%) 
      cases in laryngeal squamous cell carcinoma (LSCC) tissues, 7 (7/16, 43.75%) cases 
      in paracancerous tissues and only 2 (2/16, 12.5%) cases in normal tumor tissues. 
      Our quantitative RT-PCR assays further showed that alpha2delta1+ LSCC cells expressed 
      significantly higher levels of stem cell-associated genes and drug efflux and 
      resistance genes versusalpha2delta1- cells. Sphere-forming assays demonstrated higher 
      sphere-forming efficiency in the alpha2delta1+versusalpha2delta1- subpopulation. Our Matrigel 
      assays showed that alpha2delta1+ cells exhibited significantly greater invasive and 
      migratory ability than alpha2delta1- cells. Furthermore, the percentage of purified alpha2delta1+ 
      in TU686 and TU212 cells treated cisplatin or paclitaxel was significantly higher 
      than that of the control group. Tumor xenograft assays revealed that the 
      tumorigenicity of alpha2delta1+ cells was much higher than alpha2delta1- cells. In conclusion, a 
      alpha2delta1+ subpopulation with CSC-like property was present in laryngeal cancer and 
      possessed high self-renewal activity and was sufficient for tumor growth, 
      differentiation, migration, invasion, and chemotherapeutic resistance. They could 
      represent a promising therapeutic target for LSCC.
FAU - Huang, Chaoping
AU  - Huang C
AD  - Department of Otolaryngology and Head and Neck Surgery, Beijing Friendship 
      Hospital, Capital Medical University, Beijing 100050, China.
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Chengdu Medical College, Chengdu 610500, Sichuan, China.
AD  - Department of Otolaryngology and Head and Neck Surgery, Beijing Friendship 
      Hospital, Capital Medical University, Beijing 100050, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Otolaryngology and Head and Neck Surgery, Beijing Friendship 
      Hospital, Capital Medical University, Beijing 100050, China.
AD  - Department of Otolaryngology and Head and Neck Surgery, Beijing Friendship 
      Hospital, Capital Medical University, Beijing 100050, China.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education), Department of Cell Biology, Peking University Cancer Hospital and 
      Institute, Beijing 100142, China.
FAU - Zhang, Aobo
AU  - Zhang A
AD  - Department of Otolaryngology and Head and Neck Surgery, Beijing Friendship 
      Hospital, Capital Medical University, Beijing 100050, China.
FAU - Lu, Cheng
AU  - Lu C
AD  - Department of Otolaryngology and Head and Neck Surgery, Beijing Friendship 
      Hospital, Capital Medical University, Beijing 100050, China.
FAU - Wang, Zhenxiao
AU  - Wang Z
AD  - Department of Otolaryngology and Head and Neck Surgery, Beijing Friendship 
      Hospital, Capital Medical University, Beijing 100050, China.
FAU - Liu, Liangfa
AU  - Liu L
AD  - Department of Otolaryngology and Head and Neck Surgery, Beijing Friendship 
      Hospital, Capital Medical University, Beijing 100050, China.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Calcium Channels, L-Type)
SB  - IM
EIN - Cancer Biomark. 2019;25(3):409. PMID: 31177204
MH  - Animals
MH  - Apoptosis
MH  - Biomarkers, Tumor
MH  - Calcium Channels, L-Type/*genetics/metabolism
MH  - Carcinoma, Squamous Cell/*genetics/metabolism/pathology
MH  - Cell Differentiation
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic
MH  - Disease Models, Animal
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/metabolism/pathology
MH  - Mice
MH  - Neoplastic Stem Cells/*metabolism/pathology
MH  - Prognosis
MH  - Xenograft Model Antitumor Assays
PMC - PMC6398553
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - cancer stem cells
OT  - alpha2delta1
COIS- The authors declare that they do not have any potential conflict of interests in 
      relation to the contents of this manuscript.
EDAT- 2018/11/27 06:00
MHDA- 2019/06/14 06:00
PMCR- 2019/03/04
CRDT- 2018/11/27 06:00
PHST- 2018/11/27 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/11/27 06:00 [entrez]
PHST- 2019/03/04 00:00 [pmc-release]
AID - CBM181947 [pii]
AID - 10.3233/CBM-181947 [doi]
PST - ppublish
SO  - Cancer Biomark. 2019;24(1):97-107. doi: 10.3233/CBM-181947.